Literature DB >> 17640696

Antiviral activity of a Rac GEF inhibitor characterized with a sensitive HIV/SIV fusion assay.

Suzanne Pontow1, Brooke Harmon, Nancy Campbell, Lee Ratner.   

Abstract

A virus-dependent fusion assay was utilized to examine the activity of a panel of HIV-1, -2, and SIV isolates of distinct coreceptor phenotypes. This assay allowed identification of entry inhibitors, and characterization of an antagonist of a Rac guanine nucleotide exchange factor, as an inhibitor of HIV-mediated fusion.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17640696      PMCID： PMC2174213          DOI： 10.1016/j.virol.2007.06.022

Source DB:  PubMed          Journal:  Virology        ISSN： 0042-6822            Impact factor:   3.616


  28 in total

Review 1.  Rho and Rac take center stage.

Authors:  Keith Burridge; Krister Wennerberg
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

2.  A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes.

Authors:  Marielle Cavrois; Carlos De Noronha; Warner C Greene
Journal:  Nat Biotechnol       Date:  2002-09-30       Impact factor: 54.908

Review 3.  HIV-1 entry and its inhibition.

Authors:  T C Pierson; R W Doms
Journal:  Curr Top Microbiol Immunol       Date:  2003       Impact factor: 4.291

4.  Rational design and characterization of a Rac GTPase-specific small molecule inhibitor.

Authors:  Yuan Gao; J Bradley Dickerson; Fukun Guo; Jie Zheng; Yi Zheng
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-05       Impact factor: 11.205

5.  Evidence for common structural determinants of human immunodeficiency virus type 1 coreceptor activity provided through functional analysis of CCR5/CXCR4 chimeric coreceptors.

Authors:  S Pontow; L Ratner
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

6.  Rapid phenotypic drug susceptibility assay for HIV-1 with a CCR5 expressing indicator cell line.

Authors:  M Pirounaki; N A Heyden; M Arens; L Ratner
Journal:  J Virol Methods       Date:  2000-03       Impact factor: 2.014

7.  Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor.

Authors:  C A Derdeyn; J M Decker; J N Sfakianos; Z Zhang; W A O'Brien; L Ratner; G M Shaw; E Hunter
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

8.  Role of human immunodeficiency virus type 1 matrix phosphorylation in an early postentry step of virus replication.

Authors:  Rajnish Kaushik; Lee Ratner
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

9.  Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity.

Authors:  Tsutomu Murakami; Sherimay Ablan; Eric O Freed; Yuetsu Tanaka
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

10.  HIV-1 Nef binds the DOCK2-ELMO1 complex to activate rac and inhibit lymphocyte chemotaxis.

Authors:  Ajit Janardhan; Tomek Swigut; Brian Hill; Michael P Myers; Jacek Skowronski
Journal:  PLoS Biol       Date:  2004-01-20       Impact factor: 8.029
View more
  9 in total

Review 1.  Rho'ing in and out of cells: viral interactions with Rho GTPase signaling.

Authors:  Céline Van den Broeke; Thary Jacob; Herman W Favoreel
Journal:  Small GTPases       Date:  2014-03-24

2.  Rift Valley fever virus strain MP-12 enters mammalian host cells via caveola-mediated endocytosis.

Authors:  Brooke Harmon; Benjamin R Schudel; Dianna Maar; Carol Kozina; Tetsuro Ikegami; Chien-Te Kent Tseng; Oscar A Negrete
Journal:  J Virol       Date:  2012-09-19       Impact factor: 5.103

3.  One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates.

Authors:  Paul W Denton; Florence Othieno; Francisco Martinez-Torres; Wei Zou; John F Krisko; Elisa Fleming; Sima Zein; Daniel A Powell; Angela Wahl; Youn Tae Kwak; Brett D Welch; Michael S Kay; Deborah A Payne; Philippe Gallay; Ettore Appella; Jacob D Estes; Min Lu; J Victor Garcia
Journal:  J Virol       Date:  2011-05-18       Impact factor: 5.103

4.  Role of Abl kinase and the Wave2 signaling complex in HIV-1 entry at a post-hemifusion step.

Authors:  Brooke Harmon; Nancy Campbell; Lee Ratner
Journal:  PLoS Pathog       Date:  2010-06-17       Impact factor: 6.823

5.  Induction of the Galpha(q) signaling cascade by the human immunodeficiency virus envelope is required for virus entry.

Authors:  Brooke Harmon; Lee Ratner
Journal:  J Virol       Date:  2008-07-16       Impact factor: 5.103

Review 6.  CDC42 Use in Viral Cell Entry Processes by RNA Viruses.

Authors:  Thomas Swaine; Matthias T Dittmar
Journal:  Viruses       Date:  2015-12-10       Impact factor: 5.048

Review 7.  All-Round Manipulation of the Actin Cytoskeleton by HIV.

Authors:  Alberto Ospina Stella; Stuart Turville
Journal:  Viruses       Date:  2018-02-05       Impact factor: 5.048

Review 8.  Chemokines and Chemokine Receptors: Accomplices for Human Immunodeficiency Virus Infection and Latency.

Authors:  Zhuo Wang; Hong Shang; Yongjun Jiang
Journal:  Front Immunol       Date:  2017-10-16       Impact factor: 7.561

Review 9.  HIV-1 Hijacking of Host ATPases and GTPases That Control Protein Trafficking.

Authors:  Lucas A Tavares; Yunan C Januário; Luis L P daSilva
Journal:  Front Cell Dev Biol       Date:  2021-07-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.